Research Solutions launches AI-based clinical trial tool

HENDERSON, Nev. – Research Solutions Inc. (NASDAQ: RSSS), known for providing cloud-based workflow solutions, today announced the release of their new Clinical Trial Landscape software. This AI-powered tool aims to enhance the accessibility and analysis of clinical trial information for professionals in the medical field.

The Clinical Trial Landscape is designed to assist medical science liaisons, medical affairs specialists, and clinical development teams in efficiently navigating and synthesizing vast amounts of clinical trial data. The software offers features like adverse event filtering, detailed analytics, and guided search capabilities, enabling users to identify key Principal Investigators (PIs) and relevant publications quickly.

Eléonore Dixon-Roche, Product Manager at Research Solutions, emphasized the software's ability to streamline the research process by providing comprehensive, bias-free access to global clinical trial information. The platform aggregates content from trusted registries and databases, including ClinicalTrials.gov and PubMed, to provide users with up-to-date data.

Research Solutions anticipates that the Clinical Trial Landscape will reinforce their role as a leader in scientific data integration and support their growth by attracting new users and strengthening existing customer relationships. The launch follows the company's recent acquisitions and the introduction of their Technology Landscape solution, contributing to a growing ecosystem aimed at fostering innovation in healthcare and medical research.

The company, which serves over 70 percent of the top pharmaceutical companies, as well as universities and emerging businesses, continues to expand its portfolio of AI and NLP technology-powered products. The Clinical Trial Landscape's launch is in line with Research Solutions' commitment to advancing the scientific community's progress.

For those interested in learning more about the Clinical Trial Landscape and its impact on healthcare and medical sector innovations, Research Solutions has announced an upcoming webinar. This news article is based on a press release statement from Research Solutions, Inc.

As Research Solutions Inc. (NASDAQ: RSSS) unveils its Clinical Trial Landscape software, the company's financial health and market performance provide additional context for investors and industry observers. The latest data from InvestingPro indicates a market capitalization of $91.32 million, showcasing the company's size within the competitive tech landscape. Despite facing challenges, such as a negative P/E ratio of -192.38, reflecting its recent lack of profitability, Research Solutions has been experiencing positive revenue growth. In the last twelve months as of Q2 2024, the company reported a revenue increase of 17.15%, highlighting its potential for expansion and scaling.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

InvestingPro Tips suggest that while Research Solutions has not been profitable over the last twelve months, analysts are optimistic, predicting that the company will turn a profit this year. This could be a pivotal moment for the company, particularly as it launches innovative products like the Clinical Trial Landscape. Additionally, despite short-term obligations exceeding liquid assets, the company has shown a strong return over the last three months, with a price total return of 28.79%. This suggests that investors are responding well to the company's strategic moves and market positioning.

For those considering an investment in Research Solutions, there are 9 additional InvestingPro Tips available at https://www.investing.com/pro/RSSS. These tips could provide further insights into the company's financial nuances and market potential. To access these insights and more, use coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing your investment research with valuable data and expert analysis.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.